Cleared Traditional

K183390 - QNext and DG-PT

K183390 is the FDA 510(k) clearance for QNext and DG-PT by Diagnostic Grifols, S.A.. It is a Class 2 Hematology device (product code JPA) cleared through the Traditional 510(k) pathway after a 258-day FDA review.

K183390 · Diagnostic Grifols, S.A. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2019
Decision
258d
Days
Class 2
Risk

K183390 is an FDA 510(k) clearance for the QNext and DG-PT. Classified as System, Multipurpose For In Vitro Coagulation Studies (product code JPA), Class II - Special Controls.

Submitted by Diagnostic Grifols, S.A. (Partes Del Valles, ES). The FDA issued a Cleared decision on August 21, 2019 after a review of 258 days - an extended review cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.5425 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Hematology review framework, consistent with the majority of Class II 510(k) submissions.

View all Diagnostic Grifols, S.A. devices

Submission Details

510(k) Number K183390 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 06, 2018
Decision Date August 21, 2019
Days to Decision 258 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
145d slower than avg
Panel avg: 113d · This submission: 258d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code JPA System, Multipurpose For In Vitro Coagulation Studies
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.5425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - JPA System, Multipurpose For In Vitro Coagulation Studies

All 116
Devices cleared under the same product code (JPA) and FDA review panel - the closest regulatory comparables to K183390.
ROTEM sigma Thromboelastometry System
K201440 · Tem Innovations GmbH · Jul 2022
GEM Hemochron 100 System, GEM Hemochron 100 Activated Clotting Time Plus Test (ACT+), GEM Hemochron 100 Low Range Activated Clotting Time Test (ACT-LR), directCHECK ACT+ Whole Blood Control, Level 1 and Level 2, directCHECK ACT-LR Whole Blood Control, Level 1 and Level 2
K202101 · Accriva Diagnostics, Inc. · Dec 2021
Hemochron Signature Elite
K193041 · Accriva Diagnostics, Inc. · Nov 2019
TEG 6s Hemostasis System, TEG 6s Citrated: K, RT, FF Assay Cartridge
K183160 · Haemonetics Corporation · May 2019
CP3000 Coagulation analyzer, Coagpia AT Reagent, Coagpia Calibrator, Coagpia Control Set
K173202 · Sekisui Medical Co., Ltd. · May 2018
ACL AcuStar
K170314 · Instrumentation Laboratory CO · Mar 2017